These results suggest that Ki-67 expression detected by both IHC and qRT-PCR is considered to be predictor of clinical response to neoadjuvant chemotherapy in
locally advanced breast cancer. This result also suggests that Ki-67 mRNA expression detected by qRT-PCR and Ki-67 expression using IHC have similar results.
[21] Neoadjuvant chemotherapy has been used to treat women with
locally advanced breast cancer in an attempt to render the tumour operable.
"Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with
locally advanced breast cancer. Oncology 2010; 79(1): 324-30.
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and
locally advanced breast cancer: SWOG 0012.
The effects of chemotherapy on breast cancer tissue in
locally advanced breast cancer. Histopathology.
Studying actual neoadjuvant therapy outcomes in 20 patients with
locally advanced breast cancer who were in a clinical trial in which they underwent four cycles of neoadjuvant chemotherapy and hyperthermia, followed by surgery, the MRI-based scoring system had 91% sensitivity and 89% specificity for predicting neoadjuvant treatment response.
With this background, a descriptive study was aimed to determine the correlation between the WHO response criteria and RECIST response criteria in
Locally Advanced Breast Cancer following Neoadjuvant chemotherapy.
Neoadjuvant therapy for
locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.
According to the company, the Phase 2 study is designed to evaluate whether the combination of MM-121 with paclitaxel is more effective than treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen in two patient cohorts of HER2-negative,
locally advanced breast cancer patients.
Locally Advanced Breast Cancer (LABC) constitutes more than 50 to 70% of the patients presenting for treatment.
Treatment for women with stage III or
locally advanced breast cancer. CMAJ 2004;170(6):983-994.
The company's Phase 2 study is designed to evaluate whether the combination of MM-121 with paclitaxel is more effective than treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen in two patient groups of HER2-negative,
locally advanced breast cancer patients.
